Evidence map›Paper›PMID 32894619›Full record

ArticleGlia2021

Differential effects of integrase strand transfer inhibitors, elvitegravir and raltegravir, on oligodendrocyte maturation: A role for the integrated stress response.

Lindsay M Roth, Bassam Zidane, Lindsay Festa, Raj Putatunda, Micah Romer, Hubert Monnerie, Kelly L Jordan-Sciutto, Judith B Grinspan

Open access · greenAbstract read
In one paragraph

Article in Glia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model.International journal of molecular sciences · 2022
    Review
  13. HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Lindsay M RothDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-6452-3386
Bassam ZidaneDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Lindsay FestaDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Raj PutatundaDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Micah RomerDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Hubert MonnerieDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kelly L Jordan-SciuttoDepartment of Basic and Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Judith B GrinspanDepartment of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0940-5314
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US

Funding

TRANSGENIC MOUSE MODELS OF MENTAL RETARDATIONP30HD026979 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI YUDKOFF, MARC · 1990 to 2015
$15.3M
PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGYT32GM008076 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A · 1985 to 2023
$10.8M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
The Intellectual and Developmental Disabilities Research Center (IDDRC) at CHOP/PennP50HD105354 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ERIC D MARSH, ROBERT Thomas SCHULTZ · 2021 to 2026
$9.2M
Oligodendrocyte damage and dysfunction in HIV associated neurocognitive disorderR01MH098742 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI JUDITH B GRINSPAN, Kelly L Jordan-Sciutto · 2012 to 2026
$9.0M
Training Program in Neurodevelopmental DisabilitiesT32NS007413 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI AMELIA J EISCH, ERIC D MARSH · 1998 to 2026
$8.9M
Role of PERK haplotypes in HIV-Associated Neurocognitive DisordersR01MH109382 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI JORDAN-SCIUTTO, KELLY L · 2016 to 2020
$3.1M
Effect of HIV and ART therapy on developmental myelinationR21MH118121 · NIMH · CHILDREN'S HOSP OF PHILADELPHIA · PI GRINSPAN, JUDITH B, JORDAN-SCIUTTO, KELLY L · 2018 to 2019
$471k
NIAID NIH HHS T32 AI007632NICHD NIH HHS P30 HD026979NICHD NIH HHS P50 HD105354NIGMS NIH HHS T32 GM008076NIMH NIH HHS R01 MH098742NIMH NIH HHS R01 MH109382NIMH NIH HHS R21 MH118121NINDS NIH HHS T32 NS007413
6 · The paper itself

Abstract

Regardless of adherence to combined antiretroviral therapy, white matter and myelin pathologies persist in patients with HIV-associated neurocognitive disorders, a spectrum of cognitive, motor, and behavioral impairments. We hypothesized that antiretroviral therapy alters the maturation of oligodendrocytes which synthesize myelin. We tested whether specific frontline integrase strand transfer inhibitors would alter oligodendrocyte differentiation and myelination. To model the effect of antiretrovirals on oligodendrocytes, we stimulated primary rat oligodendrocyte precursor cells to differentiate into mature oligodendrocytes in vitro in the presence of therapeutically relevant concentrations of elvitegravir or raltegravir and then assessed differentiation with lineage specific markers. To examine the effect of antiretrovirals on myelination, we treated mice with the demyelinating compound cuprizone, for 5 weeks. This was followed by 3 weeks of recovery in absence of cuprizone, during which time some mice received a daily intrajugular injection of elvitegravir. Brains were harvested, sectioned and processed by immunohistochemistry to examine oligodendrocyte maturation and myelination. Elvitegravir inhibited oligodendrocyte differentiation in vitro in a concentration-dependent manner, while raltegravir had no effect. Following cuprizone demyelination, administration of elvitegravir to adult mice reduced remyelination compared with control animals. Elvitegravir treatment activated the integrated stress response in oligodendrocytes in vitro, an effect which was completely blocked by pretreatment with the integrated stress response inhibitor Trans-ISRIB, preventing elvitegravir-mediated inhibition of oligodendrocyte maturation. These studies demonstrate that elvitegravir impairs oligodendrocyte maturation and remyelination and that the integrated stress response mediates this effect and may be a possible therapeutic target.

Indexed as

OligodendrogliaAnimalsCell DifferentiationCuprizoneHIV InfectionsHumansIntegrasesMiceMice, Inbred C57BLMyelin SheathQuinolonesRaltegravir PotassiumRatsCuprizoneelvitegravirIntegrasesQuinolonesRaltegravir PotassiumHANDHIVintegrated stress responsemyelinneuroinflammationoligodendrocytes

Identifiers

PMID32894619
PMCPMC7736549
OpenAlexW3084093379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.